Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Postmenopausal Estrogen ◽

Epidermal Growth ◽

Randomized Phase 2

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1005-1005 ◽

Cited By ~ 1

Author(s):

Guy Heinrich Maria Jerusalem ◽

Elena Kovalenko ◽

Denise A. Yardley ◽

Richard H. De Boer ◽

Sara A. Hurvitz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdw365.01 ◽

2016 ◽

Vol 27 ◽

pp. vi68 ◽

Cited By ~ 5

Author(s):

M. Royce ◽

C. Villanueva ◽

M. Ozguroglu ◽

T. Bachelot ◽

S. Azevedo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.08.009 ◽

2020 ◽

Vol 20 (2) ◽

pp. e173-e180 ◽

Cited By ~ 3

Author(s):

Hope S. Rugo ◽

Richard S. Finn ◽

Karen Gelmon ◽

Anil A. Joy ◽

Nadia Harbeck ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Objective Response ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Survival Outcome ◽

Free Survival ◽

Evaluation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status Before and After Neoadjuvant Chemotherapy in Breast Cancer Patients

Indian Journal of Surgery ◽

10.1007/s12262-020-02380-y ◽

2020 ◽

Author(s):

Adarsh Verma ◽

Amrita Ghosh Kar ◽

Ram Niwas Meena ◽

S. C. U. Patne ◽

Shashi Prakash Mishra ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Breast Cancer Patients ◽

Before And After ◽

Abstract P3-01-04: DETECT V – Expression analysis of human epidermal growth factor receptor 2 and estrogen receptor on circulating tumor cells of metastatic breast cancer patients

10.1158/1538-7445.sabcs18-p3-01-04 ◽

2019 ◽

Author(s):

T Fehm ◽

F Meier-Stiegen ◽

S Riethdorf ◽

B Rack ◽

F-A Taran ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽